Qiagen Syndromic Testing System, Respiratory Panel Garner FDA Clearance

May 20, 2019

|

NEW YORK (GenomeWeb) – Qiagen said today that its QiaStat-Dx syndromic testing system and multiplex respiratory pathogen panel have received 510(k) clearance from the US Food and Drug Administration.

With the clearance, Qiagen is commercially launching the products in the US, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Dec

02

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

This webinar will discuss how Moffitt Cancer Center  has implemented a new capture-based application to accurately assess myeloid malignancies  by detecting complex variants in challenging genes  in a single experiment. 

Menu